Balyasny Asset Management LLC Iveric Bio, Inc. Transaction History

Balyasny Asset Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$18.67 - $24.56 $6.71 Million - $8.83 Million	359,422 Added 42.62%	1,202,733 $29.3 Million
Q4 2022 Feb 14, 2023	SELL	$17.24 - $23.95 $14.5 Million - $20.1 Million	-839,924 Reduced 49.9%	843,311 $18.1 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $11.1 Million - $21.9 Million	1,180,342 Added 234.71%	1,683,235 $30.2 Million
Q2 2022 Aug 15, 2022	BUY	$9.12 - $18.9 $4.59 Million - $9.5 Million	502,893 New	502,893 $4.84 Million
Q1 2022 May 16, 2022	SELL	$12.15 - $16.83 $408,580 - $565,959	-33,628 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$13.83 - $18.78 $465,075 - $631,533	33,628 New	33,628 $562,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.